



# HETERO LABS LIMITED

"Hetero Corporate", 7-2-A2, Industrial Estates, Sanath Nagar, Hyderabad - 500 018. Telangana, INDIA.  
Tel : 0091-40-23704923/24/25, Fax : 0091-40-23704035, 23813359  
E-mail : [contact@heterodrugs.com](mailto:contact@heterodrugs.com) URL : <http://www.heterodrugs.com>  
CIN: U24110TG1989PLC009723

To,  
**Dr. Ekaterine Tikaradze**  
**Ministry of Health**  
**Tbilisi, Georgia**

**Subject: Availability of Favipiravir, a potential drug for mild to moderate COVID-19 patients**

Dear Madam,  
Greetings from Hetero Group, Hyderabad.

We are pleased to inform that Hetero has developed the generic Favipiravir, to make it available and accessible for COVID-19 patients. As a leading drug manufacturing company in Antivirals, Hetero has developed the technology and initiated commercial production of Favipiravir API and Formulation, which is being considered for COVID-19.

Favipiravir has been authorised for Restricted Emergency Use in Russia and India for mild to moderate COVID-19 patients, considering the favourable outcomes in clinical studies. All the data is available in public domain. We anticipate various countries may consider this as part of their treatment options to combat COVID 19.

We would like to work with you to understand the requirements on this product and support during this health emergency. We are available to provide additional information on this product.

Recently, Hetero has successfully launched Remdesivir, manufactured under a license from Gilead Sciences, Inc., for severe COVID-19 patients, and the availability of Favipiravir marks our continued commitment to combat COVID-19.

HETERO stands to offer continuous support to the Citizens of your Country at all times.

Thanking You.

Yours Truly,

**Mr. Vinay Dixit**  
**General Manager- CIS,**  
**Hetero Labs Ltd,**  
**Hyderabad, India**  
**Email: [vinay.d@heterodrugs.com](mailto:vinay.d@heterodrugs.com)**  
**Phone No.: +91-9100109463**

*[Handwritten signature]*  
04.08.2020

